# RonanRX: Personalized Peptide and GLP-1 Therapies

Revolutionizing healthcare with software-enabled personalized drug manufacturing

- **Source:** [Hacker News: Front Page](https://brifing.si/source/b07aa772-b1a0-4a76-aa18-719c6f9e2dde)
- **Published:** 2026-09-02
- **Original article:** <https://ronanrx.com/>
- **On Brifing:** https://brifing.si/s/99e0c332-d97c-42a2-86f6-4e473a6c77c8

## Idea born from pandemic experience

Founder Lloyd built one of the largest mask manufacturing facilities in the US during the pandemic, reaching 1 million masks daily capacity. He's now applying this vertically integrated model, optimized with software and machine learning, to the pharmaceutical industry. The $50M experience forms RonanRX's foundation.

## Personal health journey

Lloyd's 18-month experience with GLP-1 drug tirzepatide yielded remarkable results: His congenital aortic stenosis condition improved so significantly that open-heart surgery expected in his 40s might now be delayed until his 70s-80s. This experience crystallized personalized medicine's potential.

## Current system gaps

Telehealth, electronic health records, prescription software, manufacturing and logistics systems operate in silos. Standard-dose GLP-1s prove inadequate for patients' varied responses, while pharmacies have limited personalization capabilities.

## Integrated solution

RonanRX analyzes patient medical records, lab results and wearable device data. It aims to improve treatment efficacy by managing all processes - from prescription to production, quality control to distribution - on a single platform.

## Feedback loop

The system's most innovative feature dynamically adjusts treatment based on patient response data during therapy. This data-driven approach is shaping the future of personalized medicine.

## Cost advantage

By eliminating intermediaries through vertical integration, RonanRX can offer drugs at 3-10x more affordable prices than market rates. Controlling the entire supply chain from molecule level enables this competitive pricing.

## Starting with GLP-1s

While initially focusing on GLP-1 agonists and peptides for obesity and diabetes treatment, the company ultimately aims to become a personalized drug manufacturing platform. Regulatory challenges in this field pose significant hurdles.

## Healthcare transformation potential

RonanRX's model demonstrates how data-driven personalization and vertical integration could revolutionize the pharmaceutical industry. If successful, it may usher in a new era in chronic disease management.

## Sources covering this story

- https://ronanrx.com/ — 

---

_Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._